Companies · Biotechnology

Phenomix CORP

SAN DIEGO · Biotechnology

Diligence memoA one-page analyst read on Phenomix CORP — recommendation, valuation, rhythm, risks.
$6.0M
Total raised · real
1
Rounds
Latest step-up
Top 54%
Sector rank · raised
Series A
Latest stage · inferred · Sun Feb 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Phenomix CORP looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.08× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
  • Within the normal band (108% of peer median) for its niche.
Dormant
  • Last raise 16.3 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Phenomix CORP is one of 4291 Biotechnology companies tracked from SAN DIEGO. By capital raised it ranks mid-pack (ahead of 47% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2010-02-28 Raised $6.0M (real) Modeled valuation $215M (est)$6.0M$215MSeries A2010

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.0M · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$215.3M
Base estimate est.
$6.5M
Conservative case
$1.2B
Upside case
$27.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
16.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
16.3 yr
On record since
2010
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 3.4× above median
This company$215.3M
Sector median$64.2M

Raised more than 47% of sector peers (real $). Modeled value above 73% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #43 of 92.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)Phenomix CORP (this company) Raised $6.0M · modeled $215.3M (est)Phenomix CORP
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
Phenomix CORP this companySeries A$6.0M$215.3M1.08×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.0M2010-02-28$27.1M$215.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.0M2010-02-28
    • First recorded raise — entered as Series A.
Intelligence
Modeled next raise
$9.5M
Modeled next size est.range $6.2M$15.2M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Laura Shawver5 other2010-02
Brian Baker4 other2010-02
John Diekman2 other2010-02
ANTON GIORGIO FAILLA1 other2010-02
Angela Birchler2010-02
Damion E. Wicker2010-02
Daniel Giorgio Janney2010-02
Deepika Giorgio Pakianathan2010-02
Hans-Peter Guler2010-02
James Giorgio Harper2010-02
Marie O'Farrell2010-02
William Giorgio Harris2010-02
Registry & provenance

Phenomix CORP is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1424342
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Polus Inc.BiotechnologySeries A$5.9M$215.0Msame sector · same stage
MTrap Inc.BiotechnologySeries A$6.0M$216.9Msame sector · same stage
INQUE Holdings, LLCBiotechnologySeries A$6.0M$216.9Msame sector · same stage
Microvi Biotech, Inc.BiotechnologySeries A$6.0M$180.8Msame sector · same stage
Painreform Ltd.BiotechnologySeries A$6.0M$155.8Msame sector · same stage
Seer Biosciences, Inc.BiotechnologySeries A$6.0M$216.9Msame sector · same stage
Evoke Pharma IncBiotechnologySeries A$6.0M$216.9Msame sector · same stage
Ribogenics, Inc.BiotechnologySeries A$6.0M$161.9Msame sector · same stage
Frequently asked
How much funding has Phenomix CORP raised?
Phenomix CORP has raised approximately $6.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Phenomix CORP's estimated valuation?
Provath's modeled valuation for Phenomix CORP is approximately $215.3M (modeled range $6.5M–$1.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Phenomix CORP at?
Phenomix CORP's latest modeled financing stage is Series A. Its most recent recorded round closed around Sun Feb 28.
What does Phenomix CORP do and where is it based?
Phenomix CORP operates in the Biotechnology sector, based in SAN DIEGO.
Explore related

See where Phenomix CORP sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Phenomix CORP, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.